Congress admits biosafety gaps

This in from news editor Alla Katsnelson: At a congressional hearing on linkurl:biosafety;http://www.the-scientist.com/news/display/53626/ today (October 4), the Government Accountability Office reported that the federal government doesn't know how many labs are involved in biosafety level 3 and level 4 work, or where those labs are. Although labs working with certain "select agents" are under the oversight of the CDC, labs working with other pathogens such as SARS or Hantavirus a

By | October 4, 2007

This in from news editor Alla Katsnelson: At a congressional hearing on linkurl:biosafety;http://www.the-scientist.com/news/display/53626/ today (October 4), the Government Accountability Office reported that the federal government doesn't know how many labs are involved in biosafety level 3 and level 4 work, or where those labs are. Although labs working with certain "select agents" are under the oversight of the CDC, labs working with other pathogens such as SARS or Hantavirus are not required to report mishaps. "No single federal agency, according to 12 agencies' response to our survey, has the mission to track the overall numbers of BSL3 and BSL4 labs in the United States," the GAO wrote in linkurl:testimony;http://energycommerce.house.gov/cmte_mtgs/110-oi-hrg.100407.BSL.shtml submitted to the hearing. "Consequently, no agency is responsible for determining the risks associated with the proliferation of these labs. " The GAO's report counted 17 federal agencies funding BSL3 or BSL4 research.

Popular Now

  1. How Plants Evolved Different Ways to Make Caffeine
  2. Thomson Reuters Predicts Nobelists
    The Nutshell Thomson Reuters Predicts Nobelists

    According to citation statistics, researchers behind programmed cell death pathways and CRISPR/Cas9 are among those in line for Nobel Prizes this year.

  3. Sequencing Reveals Genomic Diversity of the Human Brain
  4. Reviewing Results-Free Manuscripts
    The Nutshell Reviewing Results-Free Manuscripts

    An open-access journal is trialing a peer-review process in which reviewers do not have access to the results or discussion sections of submitted papers.

RayBiotech